A Bipartisan Coalition of 39 State Attorneys General Urge Congressional Action on Pharmacy Benefit Manager Reform
The National Association of Attorneys General (NAAG) sent a letter to Congressional leaders on behalf of 39 attorneys general who urge congressional leaders to engage in meaningful debate and reform of the current practices of pharmacy benefit managers (PBMs) and to take decisive action to reform the way PBMs conduct business and bring more transparency…
State Attorneys General Urge Bridge Funding for the Federal Crime Victims Fund (VOCA)
A bi-partisan coalition of 42 state attorneys general urge the U.S. Senate and House of Representatives to authorize much-needed 2024 bridge funding for the federal Crime Victims Fund (the “VOCA Fund.”) The VOCA Fund supports the provision of essential direct services for crime victims and survivors across the country. According to the U.S. Department of…
54 Attorneys General Call on Congress to Study AI and Its Harmful Effects on Children
A bipartisan coalition of 54 state and territory attorneys general urge Congress to study how artificial intelligence (AI) can and is being used to exploit children through child sexual abuse material (CSAM). The attorneys general also asked Congress to propose legislation that would protect children from those abuses. The National Association of Attorneys General (NAAG)…
Bipartisan Coalition of Attorneys General Express Support for the G.U.A.R.D. VA Act
A bipartisan coalition of 44 attorneys general express support for the passage of legislative proposals included in Governing Unaccredited Representatives Defrauding (G.U.A.R.D.) Veterans Affairs (VA) Benefits Act. In a letter to congressional leaders, the attorneys general explain that the passing of the bipartisan legislation would hold unaccredited and unregulated actors accountable for targeting and preying…
Attorneys General Call on Congress to Pass the Combating Illicit Xylazine Act
A bipartisan coalition of 39 state and territory attorneys general called on leaders of Congress to pass the Combating Illicit Xylazine Act (H.R.1839/S.993). Xylazine is only approved by the U.S. Food and Drug Administration (FDA) as a veterinary medicine and in humans, it is known to depress breathing and heart rate, lower blood pressure, and…
